SUMMARY A 68-year-old black woman who was put on D-penicillamine therapy (250-500 mg per day, total dose 15 g) for rheumatoid arthritis developed ocular myasthenia gravis. Two weeks after she discontinued D-penicillamine her signs and symptoms cleared with no other treatment. Review of previous cases and possible immunological mechanisms are discussed.
D-Penicillamine is an invaluable therapeutic agent in a variety of illnesses. It is an amino acid that is a pyridoxine antagonist produced by hydrolysis of penicillin.' Beneficial use has been made of its chelating properties in metallic toxic states whether exogenous2 (lead or mercury poisoning) or endogenous1 (Wilson's disease). Since combination with cysteine yields a more soluble complex, it is potentially useful in cystinuria.4 It has been used in rheumatoid arthritis,9" progressive systemic sclerosis,7 primary biliary cirrhosis, 8 With increasing use of D-penicillamine more patients will undoubtedly present with drug induced secondary myasthenia gravis. Since ocular features are predominant, ophthalmologists should bear in mind the association of myasthenia gravis with Dpenicillamine.
